title: LXR-mediated inhibition of CD4+ T helper cells.
abstract: T(H)17 cells, which require the expression of both retinoic acid receptor-related orphan receptors α and γt (RORαand RORγt) for full differentiation and function, have been implicated as major effectors in the pathogenesis of inflammatory and autoimmune diseases. We recently demonstrated that the Liver X Receptor (LXR) agonist, T0901317 (T09), also displays high-affinity RORα and RORγ inverse activity, potentially explaining its effectiveness in various T(H)17-mediated autoimmune disease models. However, recent studies suggest that in conjunction with the RORs, LXR mediates a negative regulatory effect on T(H)17 cell differentiation. Since T09 acts on both LXRs and RORs, it presents as a valuable tool to understand how compounds with mixed pharmacology affect potential pathological cell types. Therefore, using T09, we investigated the mechanism by which the LXRs and RORs affect T(H)17 cell differentiation and function. Here we demonstrate that T09 activity at RORα and γ, not LXR, is facilitating the inhibition of T(H)17 cell differentiation and function. We also demonstrate that LXR activity inhibits the differentiation and function of T(H)1, T(H)2 and iT(reg) cells. Finally, T09 inhibited T cell proliferation and induced cell death. These data help explain much of the efficacy of T09 in inflammatory models and suggest that the generation of synthetic ligands with graded, combined LXR and ROR activity may hold utility in the treatment of inflammatory and autoimmune diseases where targeting both T(H)17 and T(H)1 cells is required.
authors.affiliation: Department of Molecular Therapeutics, The Scripps Research Institute, Jupiter, Florida, United States of America.
authors.forename: Laura A
authors.initials: LA
authors.lastname: Solt
authors.forename: Theodore M
authors.initials: TM
authors.lastname: Kamenecka
authors.forename: Thomas P
authors.initials: TP
authors.lastname: Burris
mesh_terms: D000818:Animals; D017209:Apoptosis / Q000187:drug effects; D015496:CD4-Positive T-Lymphocytes / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D002454:Cell Differentiation / Q000187:drug effects; D049109:Cell Proliferation / Q000187:drug effects; D002478:Cells, Cultured; D006801:Humans; D006845:Hydrocarbons, Fluorinated / Q000494:pharmacology; D007371:Interferon-gamma / Q000378:metabolism; D020381:Interleukin-17 / Q000235:genetics / Q000378:metabolism; D000071518:Liver X Receptors; D051379:Mice; D008810:Mice, Inbred C57BL; D057094:Nuclear Receptor Subfamily 1, Group F, Member 1 / Q000378:metabolism; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3 / Q000378:metabolism; D057093:Orphan Nuclear Receptors / Q000819:agonists / Q000378:metabolism / Q000502:physiology*; D013449:Sulfonamides / Q000494:pharmacology; D018417:Th1 Cells / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D058504:Th17 Cells / Q000187:drug effects / Q000378:metabolism / Q000502:physiology*; D018418:Th2 Cells / Q000187:drug effects / Q000378:metabolism / Q000502:physiology; D005466:Fluorocarbons; D000096926:Benzenesulfonamides
chemical_list: D006845:Hydrocarbons, Fluorinated; D007371:Interferon-gamma; D020381:Interleukin-17; D000071518:Liver X Receptors; D057094:Nuclear Receptor Subfamily 1, Group F, Member 1; D057132:Nuclear Receptor Subfamily 1, Group F, Member 3; D057093:Orphan Nuclear Receptors; D013449:Sulfonamides; C539739:Rora protein, mouse; C423915:T0901317; D005466:Fluorocarbons; D000096926:Benzenesulfonamides